Trial Profile
A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Dalcetrapib (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary disorders; Myocardial infarction; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms dal-OUTCOMES
- Sponsors Roche
- 06 Mar 2020 Results published in the Diabetes Care
- 16 Dec 2019 Results (n=1378) of a nested case cohort subgroup analysis assessing association of high density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome were published in the American Heart Journal
- 09 Aug 2017 This study has been discontinued in Belgium.